

RESEARCH ARTICLE

Editorial Process: Submission:06/17/2025 Acceptance:01/19/2026 Published:01/22/2026

Prognostic and Predictive Significance of Cancer Stem Cell Markers (*ZIP-4* and *ALDH1A1*) in Ovarian Serous Carcinoma Patients: An Immunohistochemical Study

Amany Selim Attia¹, Mohamed Abdalsalam², Ahmed S. E. M. Iraki³, Samia Hussein^{4*}, Ahmad Barakat Waley⁵, Amr Khalil⁶, Zahraa I. Aboafya⁷, Reham Sameh¹

Abstract

Background: Worldwide, ovarian cancer is the eighth most common cancer among females and the fifth leading cause of cancer-related deaths in women. In Egypt, it accounts for 4.5% of all cancer cases and ranks the fourth most common cancer among women. Cancer stem cells (CSCs) play a crucial role in tumor growth and chemoresistance. Our study examined the expression of cancer stem cell markers (*ZIP-4* and aldehyde dehydrogenase-1 member A1 (*ALDH1A1*)) in ovarian serous carcinoma tissues using immunohistochemistry. We also analyzed the relationship between their expression levels and clinicopathological features, patient survival, and response to platinum-based chemotherapy. **Subjects & Method:** This study included 55 patients with ovarian serous carcinoma. Immunohistochemical staining for *ZIP-4* and *ALDH1A1* was performed. **Results:** Statistically significant relationships were detected between high *ZIP-4* and *ALDH1A1* expressions and patient age, tumor size, presence of malignant ascites, lymphovascular invasion, elevated cancer antigen-125 (CA-125) levels, disease stage, and lymph node involvement ($P < 0.001$ for each). Additionally, the log-rank test showed that high *ZIP-4* and *ALDH1A1* expressions were associated with shorter disease-free survival (DFS) ($P = 0.002$ and <0.001 , respectively) and overall survival (OS) ($P < 0.001$ for each). **Conclusion:** Ovarian cancer stem cell markers (*ZIP-4* and *ALDH1A1*) can be considered potential prognostic markers in ovarian cancer patients. Moreover, *ZIP-4* and *ALDH1A1* expressions are related to resistance to platinum-based chemotherapy, which leads to ovarian serous carcinoma progression. Clinical implications suggest that future therapeutic regimens targeting *ZIP-4* and *ALDH1A1* may help overcome platinum-based chemotherapy resistance and improve patients outcomes.

Keywords: *ZIP-4*- *ALDH1A1*- Ovarian cancer

Asian Pac J Cancer Prev, **27 (1)**, 255-264

Introduction

Ovarian cancer is a lethal malignancy in females. It is the eighth most common cancer among females and the fifth leading cause of cancer mortality among them [1]. In Egypt, ovarian cancer represents 4.5% of all cancer cases, and it is the fourth most common cancer in women [2].

Epithelial ovarian carcinoma represents 95% of ovarian malignancies [3]. Serous ovarian carcinoma, one of the histological subtypes of epithelial ovarian carcinoma, has a high mortality rate and poor outcome [4]. Poor outcome is explained by late diagnosis at advanced stages, high

tumor recurrence, and chemotherapy resistance. Thus, it is crucial to identify potential predictive biomarkers for tumor progression, recurrence, and chemotherapy resistance, which can lead to improvements in patient diagnosis and outcomes [5].

Tumor development and treatment resistance in many cancers can be explained by cancer stem cells (CSCs). These cells are characterized by self-renewal, multipotency, and the ability to differentiate into several cells that are responsible for carcinogenesis [6, 7]. Ovarian CSCs can be responsible for cancer growth, progression, metastasis, recurrence, and chemoresistance. They can be

¹Department of Pathology, Faculty of Medicine, Zagazig University, Sharkia, Egypt. ²Department of Obstetrics & Gynaecology, Al-Ahrar Teaching Hospital, Sharkia, Egypt. ³Department of Obstetrics & Gynaecology, Faculty of Medicine, Zagazig University, Sharkia, Egypt. ⁴Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Zagazig University, Sharkia, Egypt. ⁵Department of Medical Oncology, Faculty of Medicine, Zagazig University, Sharkia, Egypt. ⁶Department of Surgical Oncology, Al-Ahrar Teaching Hospital, General Organization for Teaching Hospitals and Institutes (GOTHI), Egypt. ⁷Department of Clinical and Chemical Pathology, Institute of Medical Research and Clinical Studies, National Research Centre, Cairo, Egypt.
*For Correspondence: samiahussein82@hotmail.com

a potential targeted ovarian cancer therapy [8].

ZIP-4 is a zinc transporter. It is a cancer-related protein in many tumors [9-12]. Additionally, it is responsible for activities related to cancer stem cells [13]. Aldehyde dehydrogenase-1 member A1 (*ALDH1A1*) has been found in many neoplastic and non-neoplastic tissues. *ALDH1A1*-positive tumor cells have cancer stem properties. Additionally, its upregulation in many cancers was linked to tumor invasiveness, proliferation, neo-angiogenesis, chemoresistance, and poor survival. Furthermore, *ALDH1A1* inhibition led to increased tumor chemosensitivity. However, *ALDH1A1* expression in ovarian cancers exhibited conflicting results, where serous carcinoma was associated with poor prognosis, while other types showed opposite results [14].

In our study, *ZIP-4* and *ALDH1A1* were selected over other cancer stem cell markers because they are well-established ovarian cancer stem cell markers. *ZIP-4* promotes tumor progression and enhances stemness properties [13], while *ALDH1A1* identifies ovarian CSCs and directly correlates to platinum resistance [15]. Additionally, *ZIP-4* is an upstream regulator of *ALDH1A1*. *ZIP-4* upregulation increased *ALDH1A1* expression, suggesting a functional link between the two pathways that reinforces their combined role in ovarian cancer aggressiveness [13].

In our study, we hypothesized that the expression of cancer stem cell markers (*ZIP-4* and *ALDH1A1*) is associated with aggressive clinicopathological features, poorer survival, and chemotherapy resistance in ovarian serous carcinoma.

Materials and Methods

This prospective cohort study included 55 ovarian serous carcinoma patients who were admitted to Zagazig University Hospital, Faculty of Medicine, Zagazig University, Egypt, from March 2022 to September 2022. Follow-up was performed for 3 years. All patients were subjected to a comprehensive history taking and a thorough physical examination. The tumor marker cancer antigen-125 (CA-125) measurement was performed, along with a contrast-enhanced CT scan, MRI, or PET scan.

The patients underwent optimal surgical staging/debulking at the Obstetrics and Gynecology Department, Faculty of Medicine, Zagazig University, Egypt. After surgery, they received platinum-based chemotherapy in the Medical Oncology Department, Faculty of Medicine, Zagazig University, Egypt. Six cycles of platinum-based intravenous (IV) chemotherapy were recommended for patients with stages I (high grade) and II-IV. Paclitaxel 175 mg/m² IV was given first, followed by carboplatin AUC 5-6 given IV over 30-60 minutes. This regimen was repeated every 3 weeks. Patients were switched to a second-line treatment if they had signs of progressive disease or inadequate responses. Every 2 to 3 chemotherapy cycles, CA-125 levels and contrast-enhanced CT/MRI or PET CT scans were used to evaluate responses to treatment.

Detailed information was obtained from the participants, including age, postoperative histopathological

diagnosis, histological type, stage according to the International Federation of Gynecology and Obstetrics (FIGO) (8th edition), tumor size, lymph node metastasis, distant metastasis, ascites cytology result, chemotherapy regimen, type of surgical operation, serum CA-125 level, recurrence status, disease-free survival (DFS), progression-free survival (PFS), and overall survival (OS). DFS was calculated from the start of treatment to the time of relapse or the last follow-up visit as relapse-free. PFS was calculated as the time from the beginning of treatment to disease progression or the last follow-up visit, as progression-free. OS was calculated as the time from diagnosis to death or the last follow-up contact (censored). Distant metastasis was judged by diagnostic imaging. The study got approval from the Institutional Review Board of the Faculty of Medicine, Zagazig University, Egypt (ZU-IRB# 432/2-June-2024).

The included cases were those with definite histopathological confirmation of ovarian serous carcinoma and fulfilled clinical information. The excluded cases were of inadequate tissue material, benign tumors, borderline tumors, undifferentiated carcinomas, tumors of non-epithelial origin, metastatic tumors, incomplete clinical data, and cases with massive necrosis and fibrosis. Histopathological evaluation was performed by two blinded pathologists to minimize bias.

CA-125 measurement was performed by obtaining venous blood samples from patients. After serum preparation, CA-125 was measured using the Elecsys CA 125 II assay, which uses electrochemiluminescence (ECLIA) technology. This assay is performed on an automated Cobas e immunoassay analyzer. CA-125 measurement was performed initially at admission and frequently in follow-up.

Histopathological evaluation was performed according to the criteria of the World Health Organization (WHO) classification of tumors of the female reproductive organs. Four-micron-thickness sections were used. Staining with hematoxylin & eosin (H&E) was performed to confirm the diagnosis and tumor grade. Staining with *ZIP-4* antibody (ProteinTech, dilution 1:500) and *ALDH1A1* monoclonal antibody (EP1933Y, diluted at 1:200-400) was performed to detect their immunohistochemical (IHC) expressions.

Immunohistochemical staining was evaluated by a semiquantitative scoring method. *ZIP-4* positivity was recognized by brownish cytoplasmic coloration. *ZIP-4* was scored into no staining (0), light positive staining (1), medium positive staining (2), and strong positive staining (3). The area of positive staining was scored into <5% (0), 5-25% (1), 26-50% (2), 51-75% (3), and >75% (4). Overall scoring was obtained by multiplying the intensity and expression scores for each sample. *ZIP-4* expression was classified into high or low according to the median [16].

ALDH1A1 positivity was detected by brownish cytoplasmic coloration. Additionally, it was semiquantitatively scored according to positive tumor cells as 0 (<5%), 1 (5-20%), 2 (21 to 50%), and 3 (>51%) with subsequent classification into 2 groups: low expression (scores 0 and 1) or high expression (scores 2 and 3) [17].

Statistical analysis

SPSS 22.0 for Windows (IBM Corp.) was used for statistical analysis. Continuous variables were expressed as mean \pm SD and median (range), and the categorical variables were presented as a number (percentage). Percentages of categorical variables were compared using the X² test or Fisher's exact test as appropriate. Stratification of DFS, PFS, and OS rates was estimated using a Kaplan-Meier plot and compared using the log-rank test. All tests were two-sided. A P-value < 0.05 was considered significant.

Results

Clinicopathological Features and IHC expression

At diagnosis, the patients' ages ranged from 41 to 75 years, with a mean of 58.7 ± 9.9 years. About 67.3% of the studied patients were ≥ 50 years old, 12.7% had positive family history, 61.8% had tumor size > 5 cm, 61.8% had high-grade tumor, and 69.1% showed positive lymph node metastasis. Lymphovascular invasion occurred in 45.5% of the enrolled cases. Regarding staging, 14.5%, 16.4%, 47.3%, and 21.8% had stage I, II, III, and IV, respectively. Distant metastasis was observed in 21.8% of cases (Table 1). Low ZIP-4 expression was detected in 47.3% of patients (Figure 1B), while high ZIP-4 expression was observed in 52.7% of cases (Figure 2B). 36.4% of patients showed low ALDH1A1 expression (Figure 1C), while high ALDH1A1 expression was observed in 63.6% of cases (Figure 2C).

Association between ZIP-4 and ALDH1A1 expression and clinicopathological parameters

Statistically significant relationships were detected between high ZIP-4 and ALDH1A1 expressions and each of higher age of the studied patients, increased tumor size, presence of malignant ascites, lymphovascular invasion, high CA-125 level, advanced stage, and lymph node

metastasis (P < 0.001 for each), higher tumor grades (P = 0.001 and < 0.001 , respectively), positive family history (P = 0.02 and 0.004, respectively), and the presence of distant metastasis (P = 0.002 and 0.02, respectively) (Table 2).

Association between ZIP-4 and ALDH1A1 expression and response to chemotherapy

Compared with patients with low expressions, all patients with high ZIP-4 and high ALDH1A1 expression received chemotherapy (P=0.01 and 0.002, respectively). The majority of them showed a progressive disease course (P <0.001 for each), higher relapse (P=0.01 and <0.001 , respectively), and higher mortality (P <0.001 for each).

The progressive disease course was significantly higher among patients with high ZIP-4 expression compared to those with low expression (82.6% versus 11.1%), while stable and progressive disease courses were found to be significantly higher among patients with high ALDH1A1 expression compared to those with low expression (25%, 67.9% versus 0% and 25%, respectively). Additionally, relapse and mortality rates were significantly higher among patients with high ZIP-4 expression compared to those with low expression (83.5%, 93.1% versus 26.3% and 19.2%, respectively), and among patients with high ALDH1A1 expression compared to those with low expression (100%, 82.9% versus 16.7% and 15%, respectively). Platinum-resistant relapse was significantly higher among those with high ALDH1A1 expression (P <0.01) (Table 3).

Association between ZIP-4 and ALDH1A1 expression and patients' survival

High ZIP-4 and ALDH1A1 expressions were significantly correlated with lower disease-free survival (DFS) (P=0.001 and 0.004, respectively) and lower overall survival (OS) (P <0.001 and 0.002, respectively). However, progression-free survival (PFS) didn't show any significant differences regarding ZIP-4 or ALDH1A1




Figure 1. A: low-grade ovarian serous carcinoma with mild to moderate atypia with low mitotic activity. It occasionally forms papillary structures (x100 HPF) with attached high-power insert (x400 HPF); B: low-grade ovarian serous carcinoma with low ZIP4 cytoplasmic expression; C: low-grade ovarian serous carcinoma with low ALDH1A1 cytoplasmic expression.

Table 1. Clinicopathological Features, immunohistochemical Expression, and Outcome of the Studied Patients.

Variable	Studied group (n=55)	
	No.	%
Age		
Mean ± SD	58.7 ± 9.9	
Range	41–75	
Age group		
<50 years	18	32.70%
≥50 years	37	67.30%
Family history		
Negative	48	87.30%
Positive	7	12.70%
Baseline CA-125		
Normal	16	29.10%
High	39	70.90%
Surgery		
Surgical staging	6	10.90%
Optimal debulking	17	30.9%
Sub-optimal debulking	32	58.2%
Tumor laterality		
Unilateral	26	47.30%
Bilateral	29	52.70%
Tumor grade		
Low grade	21	38.20%
High grade	34	61.80%
Malignant ascites		
Absent	18	32.70%
Present	37	67.30%
Implants		
Absent	20	36.40%
Present	35	63.60%
Maximum tumor size		
≤5 cm	21	38.20%
>5 cm	34	61.80%
LVI		
Absent	30	54.50%
Present	25	45.50%
LN metastasis		
Negative	17	30.90%
Positive	38	69.10%
Distant metastasis		
Absent	43	78.20%
Present	12	21.80%
Residual disease		
Absent	23	41.80%
Present	32	58.20%
FIGO stage		
Stage IA	1	1.80%
Stage IB	5	9.10%
Stage IC	2	3.60%
Stage IIA	4	7.30%

Table 1. Continued

Variable	Studied group (n=55)	
	No.	%
FIGO stage		
Stage IIB	5	9.10%
Stage IIIA	11	20%
Stage IIIB	10	18.20%
Stage IIIC	5	9.10%
Stage IVA	9	16.40%
Stage IVB	3	5.50%
ZIP-4		
Low	26	47.30%
High	29	52.70%
ALDH1A1		
Low	20	36.40%
High	35	63.60%
ZIP-4/ALDH1A1		
Low/Low	16	29.10%
High/Low	4	7.30%
Low/High	10	18.20%
High/High	25	45.50%
Chemotherapy		
No	5	9.10%
Yes	50	90.90%
Response to treatment (n=32)		
Complete response	3	9.40%
Partial response	2	6.30%
Stable Disease	7	21.80%
Progressive Disease	20	62.50%
Follow-up duration (months)		
Mean ± SD	27.95±9.56	
Median (Range)	33 (6-36)	
Relapse		
Absent	15	27.30%
Present	10	18.20%
Type of relapse		
Platinum sensitive	4	-7.30%
Platinum resistance	6	-10.90%
Progression		
Absent	19	34.50%
Present	36	65.50%
Mortality		
Alive	23	41.80%
Died	32	58.20%

Categorical variables were expressed as number (percentage). Continuous variables were expressed as mean ± SD & median (range). FIGO, International Federation of Gynecology and Obstetrics; LVI, lymph-vascular invasion.

expression ($P=0.257$ and 0.252 , respectively) (Table 4). Log-Rank test showed that high ZIP-4 and ALDH1A1 expressions were associated with shorter DFS ($P=0.002$ and $P<0.001$, respectively) and shorter OS ($P<0.001$, for

Table 2. Relationship between ZIP-4 and ALDH1A1 Expression and Clinicopathological Features of the Studied Patients

Variable	All		ZIP4 expression				ALDH1A1 expression			
	(n=55)	Low (n=26)	High (n=29)	Test	p-value	Low (n=20)	High (n=35)	Test	p-value	
Age group										
<50 years	18 (32.7%)	16 (61.5%)	2 (6.9%)	18.59	<0.001**	15 (75%)	3 (8.6%)	25.5	<0.001**	
≥50 years	37 (67.3%)	10 (38.5%)	27 (93.1%)			5 (25%)	32 (91.4%)			
Family history										
Negative	48 (87.3%)	20 (76.9%)	28 (96.6%)	4.755	0.02*	14 (70%)	34 (97.1%)	8.442	0.004*	
Positive	7 (12.7%)	6 (23.1%)	1 (3.4%)			6 (30%)	1 (2.9%)			
CA-125										
Normal	16 (29.1%)	14 (53.8%)	2 (6.9%)	14.64	<0.001**	15 (75%)	1 (2.9%)	31.11	<0.001**	
High	39 (70.9%)	12 (46.2%)	27 (93.1%)			5 (25%)	34 (97.1%)			
Tumor grade										
Low grade	21 (38.2%)	18 (69.2%)	3 (10.3%)	20.14	0.001**	17 (85%)	4 (11.4%)	29.18	<0.001**	
High grade	34 (61.8%)	8 (30.8%)	26 (89.7%)			3 (15%)	31 (88.6%)			
Tumor laterality										
Unilateral	26 (47.3%)	23 (88.5%)	3 (10.3%)	33.56	<0.001**	18 (90%)	8 (22.9%)	23.01	<0.001**	
Bilateral	29 (52.7%)	3 (11.5%)	26 (89.7%)			2 (10%)	27 (77.1%)			
Malignant ascites										
Absent	18 (32.7%)	16 (61.5%)	2 (6.9%)	18.59	<0.001**	15 (75%)	3 (8.6%)	25.5	<0.001**	
Present	37 (67.3%)	10 (38.5%)	27 (93.1%)			5 (25%)	32 (91.4%)			
Maximum tumor size										
≤5 cm	21 (38.2%)	18 (69.2%)	3 (10.3%)	20.14	<0.001**	17 (85%)	4 (11.4%)	29.18	<0.001**	
>5 cm	34 (61.8%)	8 (30.8%)	26 (89.7%)			3 (15%)	31 (88.6%)			
Implants										
Absent	20 (36.4%)	16 (61.5%)	4 (13.8%)	13.5	<0.001**	15 (75%)	5 (14.3%)	20.27	<0.001**	
Present	35 (63.6%)	10 (38.5%)	25 (86.2%)			5 (25%)	30 (85.7%)			
LVI										
Absent	30 (54.5%)	25 (96.2%)	5 (17.2%)	34.43	<0.001**	18 (90%)	12 (34.3%)	15.93	<0.001**	
Present	25 (45.5%)	1 (3.8%)	24 (82.8%)			2 (10%)	23 (65.7%)			
LN metastasis										
Negative	17 (30.9%)	15 (57.7%)	2 (6.9%)	16.56	<0.001**	15 (75%)	2 (5.7%)	28.61	<0.001**	
Positive	38 (69.1%)	11 (42.3%)	27 (93.1%)			5 (25%)	33 (94.3%)			
Distant metastasis										
Absent	43 (78.2%)	25 (96.2%)	18 (62.1%)	9.337	0.002*	19 (95%)	24 (68.6%)	5.211	0.02*	
Present	12 (21.8%)	1 (3.8%)	11 (37.9%)			1 (5%)	11 (31.4%)			
Residual disease										
Absent	23 (41.8%)	17 (65.4%)	6 (20.7%)	11.25	0.001*	16 (80%)	7 (20%)	18.83	<0.001**	
Present	32 (58.2%)	9 (34.6%)	23 (79.3%)			4 (20%)	28 (80%)			
FIGO stage										
Stage IA	1 (1.8%)	1 (3.8%)	0 (0%)			1 (5%)	0 (0%)			
Stage IB	5 (9.1%)	5 (19.2%)	0 (0%)			5 (25%)	0 (0%)			
Stage IC	2 (3.6%)	2 (7.7%)	0 (0%)			2 (10%)	0 (0%)			
Stage IIA	4 (7.3%)	3 (11.5%)	1 (3.4%)	23.04	<0.001**	2 (10%)	2 (5.7%)	32.41	<0.001**	
Stage IIB	5 (9.1%)	4 (15.4%)	1 (3.4%)			5 (25%)	0 (0%)			
Stage IIIA	11 (20%)	6 (23.1%)	5 (17.2%)			2 (10%)	9 (25.7%)			
Stage IIIB	10 (18.2%)	2 (7.7%)	8 (27.6%)			1 (5%)	9 (25.7%)			
Stage IIIC	5 (9.1%)	2 (7.7%)	3 (10.3%)			1 (5%)	4 (11.4%)			
Stage IVA	9 (16.4%)	1 (3.8%)	8 (27.6%)			1 (5%)	8 (22.9%)			
Stage IVB	3 (5.5%)	0 (0%)	3 (10.3%)			0 (0%)	3 (8.6%)			

**, a highly significant difference (P<0.001); *, a significant difference (P<0.05).




Figure 2. A: High-grade ovarian carcinoma with marked nuclear atypia and solid pattern (x100 HPF) with attached high-power insert (x400 HPF); B: High-grade ovarian serous carcinoma with high *ZIP4* cytoplasmic expression; C: High-grade ovarian serous carcinoma with high *ALDH1A1* cytoplasmic expression.

both). ($P < 0.001$, for each) (Figure 3, Table 5).

Discussion

Ovarian cancer stem cells exhibit resistance to chemotherapy. Additionally, they possess the ability to self-renewal, plasticity, and tumor regeneration. The tumor microenvironment maintains ovarian cancer

stem cells by supplying nutrients and oxygen gradients, extracellular matrix interactions, and immune cell modulation. Additionally, cancer-associated fibroblasts produce growth factors and cytokines that create a protumorigenic niche, promoting CSC maintenance, invasion, and chemoresistance. Moreover, several signaling pathways support CSC, including WNT, NOTCH, PI3K/AKT/mTOR, TGF- β , JAK/STAT, Hedgehog, NF- κ B, and




Figure 3. Kaplan-Meier Survival Analysis Curve. A: showing overall survival in relation to *ZIP-4* marker; B: showing overall survival in relation to *ALDH1A1* marker; C: showing disease-free survival in relation to *ZIP-4* marker; D: showing disease-free survival in relation to *ALDH1A1* marker

Table 3. Relationship between *ZIP-4* and *ALDH1A1* Expression and Treatment Characteristics of the Studied Patients

Variable	All	<i>ZIP-4</i> expression			<i>ALDH1A1</i> expression			Test [^]	p-value
	(n=55)	Low (n=26)	High (n=29)	Test [^]	p-value	Low (n=20)	High (n=35)		
Chemotherapy									
No	5 (9.1%)	5 (19.2%)	0 (0%)	6.135	0.01*	5 (25%)	0 (0%)	9.625	0.002*
Yes	50 (90.9%)	21 (80.8%)	29 (100%)			15 (75%)	35 (100%)		
Response to treatment									
Complete	3 (9.4%)	3 (33.3%)	0 (0%)			3 (75%)	0 (0%)		
Partial	2 (6.3%)	2 (22.3%)	0 (0%)	18.82	<0.001**	0 (0%)	2 (7.1%)	23.31	<0.001
Stable disease	7 (21.8%)	3 (33.3%)	4 (17.4%)			0 (0%)	7 (25%)		**
Progressive disease	20 (62.5%)	1 (11.1%)	19 (82.6%)			1 (25%)	19 (67.9%)		
Relapse									
Absent	15 (27.3%)	14 (73.7%)	1 (16.7%)	6.17	0.01*	15 (83.3%)	0 (0%)	14.58	<0.001**
Present	10 (18.2%)	5 (26.3%)	5 (83.5%)			3 (16.7%)	7 (100%)		
Type of relapse									
Platinum sensitive	4 (7.3%)	3 (60%)	1 (20%)	1.667	0.197	3 (100%)	1 (14.3%)	6.429	0.01*
Platinum resistant	6 (10.9%)	2 (40%)	4 (80%)			0 (0%)	6 (85.7%)		
Progression									
Absent	19 (34.5%)	0 (0%)	0 (0%)	0	1	0 (0%)	0 (0%)	0	1
Present	36 (65.5%)	9 (100%)	27 (100%)			2 (100%)	34 (100%)		
Mortality									
Alive	23 (41.8%)	21 (80.8%)	2 (6.9%)	30.74	<0.001**	17 (85%)	6 (17.1%)	24.08	<0.001**
Died	32 (58.2%)	5 (19.2%)	27 (93.1%)			3 (15%)	29 (82.9%)		

[^], Chi-square test; **, a highly significant difference (P<0.001); *, a significant difference (P<0.05)

Hippo [18].

In the present study, we assessed the expression of CSC markers (*ZIP-4* and *ALDH1A1*) in serous ovarian carcinoma. High *ZIP-4* expression was observed in 52.7%

of studied cases. Statistically significant relationships were detected between high *ZIP-4* expression and increased tumor size, presence of distant metastasis, presence of malignant ascites, lymphovascular invasion, higher

Table 4. Relationship between *ZIP-4* and *ALDH1A1* Expression and Free Survival Time of the Studied Group

Variable	Low expression		High expression		Test	p-value
	<i>ZIP-4</i>	<i>ZIP-4</i>	<i>ZIP-4</i>	<i>ZIP-4</i>		
Disease-free survival (months)						
Mean ± SD	(N=19)		(N=6)		3.918	0.001*
	33.1 ± 4.04		20.6 ± 12.2			
Progression-free survival (months)						
Mean ± SD	(N=9)		(N=27)		1.152	0.257
	12.8 ± 10.4		9.4 ± 6.8			
Overall survival						
Mean ± SD	(N=26)		(N=29)			
	33.5 ± 6.4		22.9 ± 9.1		4.908	<0.001**
Variable	Low expression		High expression		Test	p-value
	<i>ALDH1A1</i>	<i>ALDH1A1</i>	<i>ALDH1A1</i>	<i>ALDH1A1</i>		
Disease-free survival (months)						
Mean ± SD	(N=18)		(N=7)			
	33 ± 7.1		22.5 ± 7.5		3.242	0.004*
Progression-free survival (months)						
Mean ± SD	(N=2)		(N=34)			
	4 ± 0		10.6 ± 7.9		-1.164	0.252
Overall survival						
Mean ± SD	(N=20)		(N=35)			
	33 ± 7.4		25.1 ± 9.5		3.209	0.002*

**, a highly significant difference (P<0.001); *, a significant difference (P<0.05)

Table 5. Relationship between *ZIP-4* and *ALDH1A1* Expression and Free Survival Time of the Studied Group

Variable	Median	95% CI	Test#	P-value
Disease-free survival <i>ZIP-4</i>				
Total	30.6 months	(27.2 – 34.1)		0.002*
Low expression	33.7 months	(31.8 – 35.7)		
High expression	20.6 months	(11.7 – 29.6)		
Disease-free survival <i>ALDH1A1</i>				
Total	30.6 months	(27.2 – 34.1)		
Low expression	33.8 months	(30.5 – 37.1)	22.23	<0.001**
High expression	22.5 months	(17 – 28.1)		
Overall survival <i>ZIP-4</i>				
Total	27.9 months	(25.4 – 30.4)	31.99	<0.001**
Low expression	33.5 months	(31.1 – 35.9)		
High expression	22.9 months	(19.6 – 26.2)		
Overall survival <i>ALDH1A1</i>				
Total	27.9 months	(25.4 – 30.4)	18.94	<0.001**
Low expression	33 months	(29.8 – 36.1)		
High expression	25.1 months	(21.9 – 28.1)		

#, Log-rank test; **, a highly significant difference (P<0.001); *, a significant difference (P<0.05)

CA-125 levels, advanced stage, higher tumor grades, and lymph node metastasis. Additionally, statistically significant relationships were detected between high *ZIP-4* expression and chemotherapy resistance, high tumor relapse and mortality. Moreover, high *ZIP-4* expression was associated with poor OS and DFS.

Similar results were found by Fan et al. [19, 20], where *ZIP-4* was overexpressed in human epithelial ovarian cancer tissues (by immunoblotting, quantitative polymerase chain reaction, and immunohistochemical staining) compared to normal and benign tissues. Additionally, *ZIP-4* overexpression increased tumorigenesis and chemoresistance in high-grade serous ovarian carcinoma. Furthermore, *ZIP-4* knockdown significantly reduced cancer cell proliferation and drug resistance. Additionally, Fan et al. [13] reported that 75% of high-grade ovarian serous carcinoma samples showed *ZIP-4* overexpression. Moreover, *ZIP-4*-positive cells exhibited self-renewal and differentiation potential and formed tumors and ascites in vivo. Furthermore, high *ZIP-4* expression contributed to chemoresistance in vitro.

The tumorigenic role of *ZIP-4* can be explained by its interaction with the *NOTCH3* pathway. *ZIP-4* acts as an upstream regulator of *NOTCH3*, responsible for CSC-like activities and tumorigenesis in high-grade ovarian serous carcinoma. Thus, the *ZIP-4*-*NOTCH3* pathway represents a possible therapeutic target in high-grade ovarian serous carcinoma [13].

Concerning *ALDH1A1*, our results showed that high *ALDH1A1* expression was observed in 63.6% of cases. Statistically significant associations were found between high *ALDH1A1* expression and higher CA-125 levels, high tumor grade, increased tumor size, presence of malignant ascites, lymphovascular invasion, lymph node metastasis, advanced tumor stages, and presence of distant metastasis. Additionally, statistically significant relationships were detected between high *ALDH1A1* expression

and chemotherapy resistance, high tumor relapse and mortality. Moreover, statistically significant relationships were found between high *ALDH1A1* expression and lower DFS and OS.

Khalifa et al. [17] found similar results. They showed a positive relationship between *ALDH1A1* overexpression and higher tumor grades. Additionally, Zhao et al. [21] found that *ALDH1A1* was elevated in patients with poor clinicopathological criteria, and was associated with FIGO stage, lymph node involvement, and distant metastasis. They also found that high *ALDH1A1* expression was significantly associated with poor OS. Another meta-analysis by Tao et al. [22] showed that high expression of *ALDH1A1* was correlated with poor OS and DFS. Moreover, Ayub et al. [23] found that overexpression of *ALDH1A1* in patients with advanced epithelial ovarian cancer after treatment was associated with poor response to chemotherapy. Additionally, Roy et al. [24] found that *ALDH1A1* isoform expression in patients with high-grade ovarian serous carcinoma was associated with poor response to platinum-based therapy. Furthermore, Izycka et al. [14] found that positive *ALDH1A1* expression can be considered an independent prognostic factor of shorter OS and PFS in patients with epithelial ovarian cancer.

The tumorigenic role of *ALDH1A1* in ovarian cancer can be explained by enhancing CSC properties. Additionally, they promote metastasis by altering metabolic pathways, enhancing angiogenesis, and inducing immune evasion. Moreover, they cause treatment resistance by detoxifying chemotherapeutic drugs and activating the Wnt/β-catenin survival pathway. *ALDH1A1*-expressing ovarian cancer cells can maintain platinum-resistance by dysregulating the cell-cycle checkpoint and DNA repair network [15]. Furthermore, *ALDH1A1* converts retinol to retinoic acid, which activates nuclear receptors to regulate gene expression, stemness, cell signaling, and DNA repair [25-29].

Frequent recurrence of ovarian cancer is an important therapeutic problem, even with an initial promising response. Additionally, resistance to chemotherapy can result in treatment failure or death. The mechanism of development of chemoresistance is possibly mediated by CSCs, which causes recurrence after chemotherapy. Chemoresistance of ovarian CSCs can also be caused by increased drug effects, CSCs quiescence, accelerated DNA repair, and autophagy [30]. The role of CSCs in metastasis in ovarian cancer is related to survival in non-adherent conditions and later adherence in non-primary sites and the creation of secondary tumors. Furthermore, plasticity of CSCs helps them to undergo epithelial-mesenchymal transition with subsequent metastasis [31].

Our results support the possibility of using the expression of cancer stem cell markers (*ZIP-4* and *ALDH1A1*) in predicting ovarian cancer patients with platinum-resistance and poor prognosis. Targeting these markers may be a promising treatment strategy. Previous studies suggested targeting *ZIP-4* via RNA interference and HDAC inhibitors [20]. Additionally, targeting *ALDH1A1* via RNA interference, small-molecule inhibitors, or pan-ALDH1A family inhibitors was investigated, as well [26, 32].

In conclusion ovarian CSC markers (*ZIP-4* and *ALDH1A1*) may be related to resistance to platinum-chemotherapy, which leads to ovarian serous carcinoma progression. So, therapeutic targets against both *ZIP-4* and *ALDH1A1* may have potential roles in overcoming platinum-resistance and improving outcomes.

Limitations of the study

The relatively small sample size is one of the limitations of this research, making its results difficult to apply to the general population. Future multi-center cohort studies with increasing sample size are recommended. This allows multivariate analysis to adjust for confounders. Furthermore, exploring targeted therapies is highly recommended.

Author Contribution Statement

ASA, RS contributed to the study conception and design. All authors were responsible for the methodology and statistical analysis of data. ASA, RS, ABW, SH wrote the manuscript draft. All authors read and approved the final manuscript.

Acknowledgements

Ethical approval and consent to participate

This study got approval from the Institutional Review Board of the Faculty of Medicine, Zagazig University (IRB#432/2-June-2024).

Availability of data and material

Available upon a reasonable request from the author.

Competing interests

The authors declare that there is no conflict of interest.

References

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA: a cancer journal for clinicians. 2021;71(1):7-33. <https://doi.org/10.3322/caac.21654>.
2. Ibrahim AS, Khaled HM, Mikhail NN, Baraka H, Kamel H. Cancer incidence in egypt: Results of the national population-based cancer registry program. J Cancer Epidemiol. 2014;2014:437971. <https://doi.org/10.1155/2014/437971>.
3. Peres LC, Cushing-Haugen KL, Anglesio M, Wicklund K, Bentley R, Berchuck A, et al. Histotype classification of ovarian carcinoma: A comparison of approaches. Gynecol Oncol. 2018;151(1):53-60. <https://doi.org/10.1016/j.ygyno.2018.08.016>.
4. Vergote I, Amant F, Kristensen G, Ehlen T, Reed NS, Casado A. Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer. Eur J Cancer. 2011;47 Suppl 3:S88-92. [https://doi.org/10.1016/s0959-8049\(11\)70152-6](https://doi.org/10.1016/s0959-8049(11)70152-6).
5. Atallah GA, Abd Aziz NH, Teik CK, Shafiee MN, Kampan NC. New predictive biomarkers for ovarian cancer. Diagnostics (Basel). 2021;11(3). <https://doi.org/10.3390/diagnostics11030465>.
6. Walcher L, Kistenmacher AK, Suo H, Kitte R, Dluczek S, Strauß A, et al. Cancer stem cells-origins and biomarkers: Perspectives for targeted personalized therapies. Front Immunol. 2020;11:1280. <https://doi.org/10.3389/fimmu.2020.01280>.
7. Ayob AZ, Ramasamy TS. Cancer stem cells as key drivers of tumour progression. J Biomed Sci. 2018;25(1):20. <https://doi.org/10.1186/s12929-018-0426-4>.
8. Królewska-Daszczyńska P, Wendlocha D, Smycz-Kubańska M, Stępień S, Mielczarek-Palacz A. Cancer stem cells markers in ovarian cancer: Clinical and therapeutic significance (review). Oncol Lett. 2022;24(6):465. <https://doi.org/10.3892/ol.2022.13585>.
9. Kang X, Chen R, Zhang J, Li G, Dai PG, Chen C, et al. Expression profile analysis of zinc transporters (*zip4*, *zip9*, *zip11*, *znt9*) in gliomas and their correlation with *idh1* mutation status. Asian Pac J Cancer Prev. 2015;16(8):3355-60. <https://doi.org/10.7314/apjcp.2015.16.8.3355>.
10. Xu X, Guo HJ, Xie HY, Li J, Zhuang RZ, Ling Q, et al. *Zip4*, a novel determinant of tumor invasion in hepatocellular carcinoma, contributes to tumor recurrence after liver transplantation. Int J Biol Sci. 2014;10(3):245-56. <https://doi.org/10.7150/ijbs.7401>.
11. Nacir M, İbiloğlu I, Alabalık U. Investigation of *zip4*, *zo-1*, and *claudin-1* expression in thyroid tumours by immunohistochemistry and real-time polymerase chain reaction methods. Pol J Pathol. 2023;74(4):248-55. <https://doi.org/10.5114/pjp.2023.134318>.
12. Zeng Q, Liu YM, Liu J, Han J, Guo JX, Lu S, et al. Inhibition of *zip4* reverses epithelial-to-mesenchymal transition and enhances the radiosensitivity in human nasopharyngeal carcinoma cells. Cell Death Dis. 2019;10(8):588. <https://doi.org/10.1038/s41419-019-1807-7>.
13. Fan Q, Zhang W, Emerson RE, Xu Y. *Zip4* is a novel cancer stem cell marker in high-grade serous ovarian cancer. Cancers (Basel). 2020;12(12). <https://doi.org/10.3390/cancers12123692>.
14. Izycka N, Rucinski M, Andrzejewska M, Szubert S, Nowak-Markwitz E, Sterzynska K. The prognostic value of cancer stem cell markers (cscs) expression-*ALDH1A1*, *CD133*, *CD44*-for survival and long-term follow-up of ovarian cancer patients. Int J Mol Sci. 2023;24(3). <https://doi.org/10.3390/ijms24032400>.
15. Meng E, Mitra A, Tripathi K, Finan MA, Scalici J,

McClellan S, et al. *ALDH1A1* maintains ovarian cancer stem cell-like properties by altered regulation of cell cycle checkpoint and DNA repair network signaling. *PLoS One.* 2014;9(9):e107142. <https://doi.org/10.1371/journal.pone.0107142>.

16. Wu DM, Liu T, Deng SH, Han R, Xu Y. *Slc39a4* expression is associated with enhanced cell migration, cisplatin resistance, and poor survival in non-small cell lung cancer. *Sci Rep.* 2017;7(1):7211. <https://doi.org/10.1038/s41598-017-07830-4>.

17. Khalifa S, Muhammad ME, Khairy MD RA, Hosni HN, Abd E AM. Aldehyde dehydrogenase 1a1 expression in ovarian epithelial tumors. *J Obstet Gynecol Cancer Res.* 2022;3(1):13-8. <https://doi.org/10.21859/joqcr.3.1.13>.

18. Alizadeh H, Akbarabadi P, Dadfar A, Tareh MR, Soltani B. A comprehensive overview of ovarian cancer stem cells: Correlation with high recurrence rate, underlying mechanisms, and therapeutic opportunities. *Mol Cancer.* 2025;24(1):135. <https://doi.org/10.1186/s12943-025-02345-3>.

19. Fan Q, Cai Q, Li P, Wang W, Wang J, Gerry E, et al. The novel zip4 regulation and its role in ovarian cancer. *Oncotarget.* 2017;8(52):90090-107. <https://doi.org/10.18632/oncotarget.21435>.

20. Fan Q, Li L, Wang TL, Emerson RE, Xu Y. A novel zip4-hdac4-vegfa axis in high-grade serous ovarian cancer. *Cancers (Basel).* 2021;13(15):3821. <https://doi.org/10.3390/cancers13153821>.

21. Zhao W, Zang C, Zhang T, Li J, Liu R, Feng F, et al. Clinicopathological characteristics and prognostic value of the cancer stem cell marker aldh1 in ovarian cancer: A meta-analysis. *Onco Targets Ther.* 2018;11:1821-31. <https://doi.org/10.2147/ott.S160207>.

22. Tao Y, Li H, Huang R, Mo D, Zeng T, Fang M, et al. Clinicopathological and prognostic significance of cancer stem cell markers in ovarian cancer patients: Evidence from 52 studies. *Cell Physiol Biochem.* 2018;46(4):1716-26. <https://doi.org/10.1159/000489586>.

23. Ayub TH, Keyver-Paik MD, Debald M, Rostamzadeh B, Thiesler T, Schröder L, et al. Accumulation of aldh1-positive cells after neoadjuvant chemotherapy predicts treatment resistance and prognosticates poor outcome in ovarian cancer. *Oncotarget.* 2015;6(18):16437-48. <https://doi.org/10.18632/oncotarget.4103>.

24. Roy M, Connor J, Al-Naimi A, Rose SL, Mahajan A. Aldehyde dehydrogenase 1a1 (*ALDH1A1*) expression by immunohistochemistry is associated with chemo-refractoriness in patients with high-grade ovarian serous carcinoma. *Hum Pathol.* 2018;73:1-6. <https://doi.org/10.1016/j.humpath.2017.06.025>.

25. Kaipio K, Chen P, Roering P, Huhtinen K, Mikkonen P, Östling P, et al. *ALDH1A1*-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by egfr/mtor-pi3k/aurora kinase inhibitors. *J Pathol.* 2020;250(2):159-69. <https://doi.org/10.1002/path.5356>.

26. Chefetz I, Grimley E, Yang K, Hong L, Vinogradova EV, Suci R, et al. A pan-aldh1a inhibitor induces necroptosis in ovarian cancer stem-like cells. *Cell Rep.* 2019;26(11):3061-75.e6. <https://doi.org/10.1016/j.celrep.2019.02.032>.

27. Wei Y, Li Y, Chen Y, Liu P, Huang S, Zhang Y, et al. Aldh1: A potential therapeutic target for cancer stem cells in solid tumors. *Front Oncol.* 2022;12:1026278. <https://doi.org/10.3389/fpone.2022.1026278>.

28. Nowacka M, Ginter-Matuszewska B, Świerczewska M, Sterzyńska K, Nowicki M, Januchowski R. Effect of *ALDH1A1* gene knockout on drug resistance in paclitaxel and topotecan resistant human ovarian cancer cell lines in 2d and 3d model. *Int J Mol Sci.* 2022;23(6). <https://doi.org/10.3390/ijms23063036>.

29. Uddin MH, Kim B, Cho U, Azmi AS, Song YS. Association of *ALDH1A1*-nek-2 axis in cisplatin resistance in ovarian cancer cells. *Helijon.* 2020;6(11):e05442. <https://doi.org/10.1016/j.helijon.2020.e05442>.

30. Li SS, Ma J, Wong AST. Chemoresistance in ovarian cancer: Exploiting cancer stem cell metabolism. *J Gynecol Oncol.* 2018;29(2):e32. <https://doi.org/10.3802/jgo.2018.29.e32>.

31. Bregenzer ME, Horst EN, Mehta P, Novak CM, Repetto T, Mehta G. The role of cancer stem cells and mechanical forces in ovarian cancer metastasis. *Cancers (Basel).* 2019;11(7):1008. <https://doi.org/10.3390/cancers11071008>.

32. Muralikrishnan V, Fang F, Given TC, Podicheti R, Chtcherbinine M, Metcalfe TX, et al. A novel *ALDH1A1* inhibitor blocks platinum-induced senescence and stemness in ovarian cancer. *Cancers (Basel).* 2022;14(14):3437. <https://doi.org/10.3390/cancers14143437>.



This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License.